CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more
CanSino Biologics Inc (CASBF) - Net Assets
Latest net assets as of September 2025: $4.93 Billion USD
Based on the latest financial reports, CanSino Biologics Inc (CASBF) has net assets worth $4.93 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.30 Billion) and total liabilities ($2.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.93 Billion |
| % of Total Assets | 67.54% |
| Annual Growth Rate | 47.9% |
| 5-Year Change | -19.12% |
| 10-Year Change | N/A |
| Growth Volatility | 120.74 |
CanSino Biologics Inc - Net Assets Trend (2016–2024)
This chart illustrates how CanSino Biologics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CanSino Biologics Inc (2016–2024)
The table below shows the annual net assets of CanSino Biologics Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.91 Billion | -7.14% |
| 2023-12-31 | $5.29 Billion | -27.03% |
| 2022-12-31 | $7.25 Billion | -15.24% |
| 2021-12-31 | $8.55 Billion | +40.80% |
| 2020-12-31 | $6.07 Billion | +312.84% |
| 2019-12-31 | $1.47 Billion | +192.75% |
| 2018-12-31 | $502.32 Million | -17.29% |
| 2017-12-31 | $607.33 Million | +183.17% |
| 2016-12-31 | $214.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CanSino Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 180121300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $247.45 Million | 5.04% |
| Other Comprehensive Income | $223.70K | 0.00% |
| Other Components | $6.60 Billion | 134.41% |
| Total Equity | $4.91 Billion | 100.00% |
CanSino Biologics Inc Competitors by Market Cap
The table below lists competitors of CanSino Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ziraat Gayrimenkul Yatirim Ortakligi AS
IS:ZRGYO
|
$541.00 Million |
|
Nanosonics Ltd
AU:NAN
|
$541.07 Million |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
$541.25 Million |
|
ANTIN INFRASTR.PRT EO 1
F:8ZU
|
$541.29 Million |
|
Ã
landsbanken Abp
LSE:0O2M
|
$540.77 Million |
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
$540.76 Million |
|
HANOF
PINK:HANOF
|
$540.45 Million |
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
$540.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CanSino Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,274,604,094 to 4,909,872,000, a change of -364,732,094 (-6.9%).
- Net loss of 378,884,000 reduced equity.
- Dividend payments of 63,780,995 reduced retained earnings.
- Share repurchases of 6,962,000 reduced equity.
- New share issuances of 7,032,000 increased equity.
- Other comprehensive income increased equity by 399,851.
- Other factors increased equity by 77,463,050.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-378.88 Million | -7.72% |
| Dividends Paid | $63.78 Million | -1.3% |
| Share Repurchases | $6.96 Million | -0.14% |
| Share Issuances | $7.03 Million | +0.14% |
| Other Comprehensive Income | $399.85K | +0.01% |
| Other Changes | $77.46 Million | +1.58% |
| Total Change | $- | -6.91% |
Book Value vs Market Value Analysis
This analysis compares CanSino Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.68x to 0.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.98 | $4.60 | x |
| 2017-12-31 | $2.78 | $4.60 | x |
| 2018-12-31 | $3.19 | $4.60 | x |
| 2019-12-31 | $5.94 | $4.60 | x |
| 2020-12-31 | $24.53 | $4.60 | x |
| 2021-12-31 | $32.31 | $4.60 | x |
| 2022-12-31 | $27.35 | $4.60 | x |
| 2023-12-31 | $21.38 | $4.60 | x |
| 2024-12-31 | $19.89 | $4.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CanSino Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -45.93%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.62x
- Recent ROE (-7.72%) is above the historical average (-11.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -23.24% | -608.31% | 0.03x | 1.52x | $-71.30 Million |
| 2017 | -10.61% | 0.00% | 0.00x | 1.43x | $-125.18 Million |
| 2018 | -27.53% | -12215.64% | 0.00x | 1.58x | $-188.51 Million |
| 2019 | -10.66% | -6865.49% | 0.00x | 1.21x | $-303.82 Million |
| 2020 | -6.53% | -1593.56% | 0.00x | 1.11x | $-1.00 Billion |
| 2021 | 23.94% | 44.52% | 0.36x | 1.49x | $1.11 Billion |
| 2022 | -13.48% | -88.21% | 0.09x | 1.70x | $-1.58 Billion |
| 2023 | -28.11% | -429.55% | 0.04x | 1.77x | $-2.01 Billion |
| 2024 | -7.72% | -45.93% | 0.10x | 1.62x | $-869.87 Million |
Industry Comparison
This section compares CanSino Biologics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CanSino Biologics Inc (CASBF) | $4.93 Billion | -23.24% | 0.48x | $540.94 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |